Long-Acting HIV Shot Works Just Fine for Patients With Adherence Issues

(MedPage Today) -- Long-acting injectable therapy was similar to daily oral therapy for maintaining viral suppression in people with HIV and adherence challenges in Africa, according to an open-label phase IIIb trial.
At 48 weeks, 91% of participants...